Search Results
Jul 29, 2026, 09:57 ET Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Phase 2 patient enrollment now fully completed.Reflecting the global commercial value of its platform, Ractigen entered into a strategic drug discovery and platform licensing collaboration with a publicly listed overseas pharmaceutical company in late 2025, valued at over $3 billion.Executive
More news about: Ractigen Therapeutics
Jul 29, 2026, 09:17 ET 思捷優達-KY、AI創薬による主力候補薬YA-101の多系統萎縮症（MSA）に対する国際第2相臨床試験において患者登録を完了
ミノ酸オキシダーゼ阻害薬（DAOI）です。炎症性サイトカインを抑制する作用を有し、主に神経炎症の軽減と神経可塑性の向上により病状を改善します。YA-101は、世界中のMSA患者にとって新たな治療選択肢となり得る薬剤として開発されています。YA-101は、U.S. Food and Drug Administration（FDA）からファストトラック指定を受けたほか、米国、日本、欧州連合（EU）の規制当局から希少疾病用医薬品指定（ODD）も受けています。MSAは、急速に進行する致死性の希少神経変性疾患です。発症は通常50歳代にみられ、患者の最大80%が診断後5年以内に
More news about: Dasher Neuroscience Holdings Inc.
Jul 29, 2026, 09:05 ET HYDRINITY® Earns Prestigious 2026 Skin Anarchy Science of Skin Award, Joining the Industry's Most Scientifically Advanced Skincare Brands
technologies including Supercharged HA™, MicroFusion™, and RetaXome™. Founded as a regenerative medicine company developing advanced wound care and drug delivery systems for oncology and hematology patients, HYDRINITY has since redefined dermatological skincare with clinically backed formulations featuring
More news about: HYDRINITY Accelerated Skin Science
Jul 29, 2026, 09:00 ET 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies
More news about: 10x Genomics, Inc.
Jul 29, 2026, 09:00 ET POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
reactions. Sodium content: Repatha contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially 'sodium-free'.Interactions: No formal drug-drug interaction studies have been conducted for Repatha. No studies on pharmacokinetic and pharmacodynamics interaction between Repatha and lipid-lowering
More news about: Amgen
Jul 29, 2026, 08:30 ET Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of
More news about: Insilico Medicine
Jul 29, 2026, 08:25 ET IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
combined with whole-breast radiation therapy and endocrine therapy.In support of its recommendation, the SIO Petition cited the U.S. Food and Drug Administration's ("FDA") marketing authorization of IceCure's ProSense® cryoablation system in October 2025. ProSense® is the
More news about: IceCure Medical
Jul 29, 2026, 08:15 ET Qnovia Secures Worldwide Exclusive License to Novel Antimicrobial Peptide from the University of Virginia
effectiveness against diverse human pathogens and shows promise for countering serious respiratory, bloodstream, skin, and soft-tissue infections."Drug-resistant bacteria represent one of the fastest-growing threats in global medicine, with antibiotic resistance already contributing to millions of deaths
More news about: Qnovia, Inc.
Jul 29, 2026, 08:03 ET More to "The Point:" SHARx and Sophie Cunningham Turn a Viral Spotlight on Prescription Affordability
far beyond basketball, SHARx says the bigger story is how trusted influencers help Americans understand how close SHARx is to solving the high-cost drug dilemma.ST. LOUIS, July 29, 2026 /PRNewswire/ -- Sophie Cunningham
More news about: SHARx
Jul 29, 2026, 08:00 ET Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
Hydreight Technologies Inc. ("Hydreight") regarding the recommendations of the U.S. Food and Drug Administration ("FDA") Pharmacy Compounding Advisory Committee ("PCAC") relating to certain peptide-related bulk drug substances.
More news about: Victory Square Technologies Inc
Jul 29, 2026, 08:00 ET Causaly and Sage Bring Full-Text Scientific Literature into AI-Powered Drug Discovery Research
biomedical knowledge graph and the world's scientific literature, Causaly enables specialized AI agents to automate scientific workflows and accelerate drug discovery and development with transparent, evidence-backed insights. Leading pharmaceutical and biotechnology organizations rely on Causaly to unlock
More news about: Causaly
Jul 29, 2026, 08:00 ET Sempre Health Launches Generics, Extending Its Adherence Platform to a Member's Full Chronic Disease Regimen
relationship that has driven Sempre's adherence outcomes on branded therapy. The same trusted channel that helps members stay on their chronic disease brand drug now reaches them across the rest of their regimen.Sempre's data shows that proactive, SMS-based engagement alone drives more than two additional
More news about: Sempre Health
Jul 29, 2026, 08:00 ET Thorne's Basic Prenatal Becomes the First Prenatal with a Bioactive Form of Folate to Earn NSF Certified for Sport® Certification
Thorne.com.* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More news about: Thorne
Jul 29, 2026, 07:10 ET Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
its Investigational New Drug (IND) application in December 2025 and has began its Phase I clinical trial evaluating Nerve Trace's safety and feasibility in surgical patients. Proceeds from the investment will support Trace's Phase II and III clinical trials toward a New Drug Application (NDA)."We're
More news about: Trace Biosciences
Jul 29, 2026, 07:00 ET PBS Biotech Joins Organoid COMMONS to Accelerate Industrialization and Scalability of Human-Relevant Models
biopharma pioneers to establish the biomanufacturing standards and scalable frameworks required to transition organoid technologies from early-stage drug discovery to commercial-scale application.
More news about: PBS Biotech Inc.
Jul 29, 2026, 07:00 ET Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
that six peptide-related bulk drug substances—BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon—be considered for inclusion on the FDA's Section 503A Bulks List. These recommendations are advisory only, do not constitute FDA approval of any substance or finished drug product, and remain subject to
More news about: Hydreight Technologies Inc.
Jul 29, 2026, 07:00 ET Triquetra Health Launches Mental Magnesium™ -- First Dual-Pathway Brain Formula Combining Patented BBB-Crossing Magtein® with ATA Mg® Neural Excitation Control
[email protected]+ (844) 272-6337triquetrahealth.comThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More news about: Triquetra Health LLC
Jul 29, 2026, 07:00 ET CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that, following a Type C Focused Meeting, the U.S. Food and Drug Administration (FDA) and the Company have aligned on Phase 2b trial endpoints and a patient population enrichment strategy for its planned registration
More news about: CalciMedica, Inc.
Jul 29, 2026, 06:59 ET Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive
More news about: Viatris Inc.
Jul 29, 2026, 06:54 ET EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.FRANKLIN LAKES, N.J. and SÃO PAULO, July
More news about: BD (Becton, Dickinson and Company)
Jul 29, 2026, 06:40 ET PTFE Market worth $3.87 billion by 2031 - Exclusive Report by MarketsandMarkets™
Plastics, Engineering Plastics, High-performance Plastics), Application (Medical Disposables, Medical Instruments & Devices, Prosthetics & Implants, Drug Delivery, Medical Packaging) - Global Forecast to 2031
More news about: MarketsandMarkets
Jul 29, 2026, 06:30 ET Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration
More news about: BioArctic
Jul 29, 2026, 06:30 ET Boston Scientific announces results for second quarter 2026
Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.4 Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed
More news about: Boston Scientific Corporation
Jul 29, 2026, 06:30 ET Entergy reports second quarter 2026 financial results
as well as higher compensation and benefits costs resulting from higher healthcare claims activity and the timing of the recognition of prescription drug rebates. The second quarter decrease was partially offset by lower bad debt expense. The year-to-date earnings decrease from higher Utility other
More news about: Entergy Corporation
Jul 29, 2026, 06:27 ET Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration
More news about: BioArctic